Why Allergan Earnings Aren’t Telling the Whole Story
Allergan reported mixed second-quarter 2016 results and announced share buybacks before markets opened Monday morning.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
The big news for Allergan PLC (NYSE: AGN) came early in the second quarter, when Pfizer Inc. (NYSE: PFE) terminated its proposed $160 billion acquisition of the Ireland-based maker of Botox. The deal was scuttled by a change in U.S. regulations related to tax inversions, and the break-up fee added $400 million to Allergan’s coffers. Allergan also completed the $40.5 billion sale of its generic drug business to Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) on August 2.
Allergan reported second-quarter 2016 results before markets opened Monday. Adjusted diluted earnings per share (EPS) came in at $3.53 and revenues were $3.68 billion. In the same period a year ago, Allergan reported EPS of $3.67 on revenues of $3.63 billion. Second-quarter results also compare to the Thomson Reuters consensus estimates for EPS of $3.34 and $4.1 billion in revenues.
On a GAAP basis, the company posted a net loss of $488 million, or $1.44 per share, including $0.19 related to the sale of its distribution business.
Quarterly revenues were up 2% year over year but were negatively affected by the loss of exclusivity on the company’s Namenda IR Alzheimer drug.
[nativounit]
Allergan guided 2016 revenues in a range of $14.65 billion to $14.9 billion and adjusted EPS in a range of $13.75 to $14.20. On a GAAP basis, the company expects to post a net loss per share of $1.95 to $2.15. Adjusted gross margin is expected to be about 89% and GAAP gross margin is tagged to be about 88%.
Analysts had been looking for 2016 adjusted EPS of $14.21 and revenues of $16.63 billion. For the third quarter, consensus estimates call for adjusted EPS of $3.61 and revenues of $4.25 billion.
Chief Financial Officer Tessa Hilado said:
Post the completion of the Teva transaction we have made significant progress toward strengthening our balance sheet to support our long-term growth. Using the proceeds of the Teva transaction and cash flows from operations in the second quarter, we have repaid $9.3 billion in debt, leaving us with $33.3 billion in total outstanding debt and approximately $27.6 billion remaining in cash. We plan to commence our share repurchase program shortly with the initial focus on repurchasing approximately $5 billion in shares over the remainder of the year. Upon the conclusion of this program, we will evaluate whether to move forward and repurchase the remaining $5 billion authorized by the Allergan board. This is in-line with our larger capitalization strategy – which is focused on maximizing value for our shareholders over the long-term.
Shares closed at $253.85 on Friday, up about 0.2% in a 52-week range of $195.50 to $325.27. The stock traded up about 0.3% in Monday’s premarket session at $254.68. The consensus price target for the shares is $292.06, according to Thomson/First Call.
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.
He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.
